George R Laking

6PUBLICATIONS
19CO-AUTHORS
Epidemiological modellingMolecular targetsTe mātai tahumaero o te Māori (Māori epidemiology)Other education not elsewhere classifiedMarketing theory
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 03, 2025
Treatment Outcomes From Erlotinib and Gefitinib in Advanced Epidermal Growth Factor Receptor-Mutated Nonsquamous Non-Small Cell Lung Cancer in Aotearoa New Zealand From 2010 to 2020: Nationwide Whole-of-Patient-Population Retrospective Cohort Study.

Phyu Sin Aye, Joanne Barnes, George Laking

|Jul 02, 2024
Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation-Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy.

Phyu Sin Aye, Joanne Barnes, George Laking

|Aug 16, 2023
Ethnic differences in the characteristics of patients with newly diagnosed lung cancer in the Te Manawa Taki region of New Zealand.

Ha Nguyen, Chunhuan Lao, Rawiri Keenan

|Jun 16, 2020
Author reply.

George Laking

|Sep 12, 2019
Pre-marketing is a type of marketing.

George Laking

|Jul 19, 2019
Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non-small-cell lung cancer in New Zealand.

Mark J McKeage, Sandar Tin Tin, Prashannata Khwaounjoo

Pageof 1

Frequent Collaborators

4 joint publications

Mark McKeage

2 joint publications

Elliott Brenman

2 joint publications

Phyu Sin Aye

2 joint publications

Joanne Barnes